Depemokimab Trial for COPD
Phase 3
981
about 4.2 years
40–80
4 sites in FL, SC, TX
What this study is about
Researchers are testing depemokimab, a new medication, as an add-on treatment for adults with moderate to severe COPD and type 2 inflammation. The trial will last for 1522 days (approximately 3 years) and involve about 981 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Depemokimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 52, Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score at Week 52
Respiratory